GlassScriptPhysician profile
Kevin Gaffney
NPI 1972506426
$34,957.20
in general payments reported to CMS, 2019-2025
64 companies · $4,630 in 2025
The $4,630 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $7,194 · 2021: $1,380 · 2022: $1,859 · 2023: $2,825 · 2024: $3,237 · 2025: $4,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,692.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,608.06 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $7,601.39 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Allergan, INC. | $6,417.03 | 2020-2022 | |
| Abbvie INC. | $1,471.20 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,308.77 | 2020-2025 | |
| Inspire Medical Systems, INC. | $987.44 | 2023-2025 | Inspire |
| Tg Therapeutics, INC. | $946.84 | 2024-2025 | |
| Emd Serono, INC. | $858.40 | 2019-2025 | Mavenclad, Mavenclad |
| Eisai INC. | $620.84 | 2020-2025 | |
| Harmony Biosciences LLC | $535.32 | 2020-2025 | Wakix |
| Neurocrine Biosciences, INC. | $495.43 | 2022-2025 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $405.41 | 2022 | |
| Pfizer INC. | $389.36 | 2023-2025 | |
| Genentech USA, INC. | $367.06 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $364.71 | 2021-2025 | Emgality, Amyvid, Kisunla |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $310.30 | 2021-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $272.01 | 2023-2025 | Xywav |
| Ucb, INC. | $270.95 | 2021-2025 | Rystiggo |
| Biogen, INC. | $270.94 | 2020-2024 | Vumerity, Tysabri, Avonex |
| Axsome Therapeutics, INC. | $248.46 | 2023-2025 | Symbravo, Sunosi |
| Argenx US, INC. | $238.98 | 2022-2025 | Vyvgart Hytrulo |
| Amgen INC. | $236.96 | 2022-2025 | Uplizna, Repatha, Aimovig |
| Grifols USA, LLC | $236.33 | 2022-2025 | Gamunex-C |
| Celgene Corporation | $191.72 | 2022-2025 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $171.63 | 2023-2025 | Hyqvia |
| Lundbeck LLC | $168.98 | 2020-2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $163.29 | 2023-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $162.72 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Acadia Pharmaceuticals INC | $160.43 | 2023-2025 | Nuplazid |
| Sk Life Science, INC. | $153.00 | 2020-2023 | |
| Genentech, INC. | $143.85 | 2020 | |
| Supernus Pharmaceuticals, INC. | $106.64 | 2022-2024 | Qelbree |
| Ge Healthcare | $78.66 | 2023 | |
| Aucta Pharmaceuticals, INC. | $73.85 | 2024-2025 | Motpoly Xr |
| Acorda Therapeutics, INC | $68.85 | 2022-2023 | Inbrija, Ampyra |
| Astrazeneca Pharmaceuticals LP | $57.83 | 2022-2023 | Andexxa |
| Livanova USA, INC. | $54.31 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Avion Pharmaceuticals | $49.60 | 2022-2023 | Dhivy |
| E.R. Squibb & Sons, L.L.C. | $47.81 | 2020 | |
| Azurity Pharmaceuticals, INC. | $46.86 | 2024-2025 | Horizant |
| Impel Pharmaceuticals INC. | $46.55 | 2023 | Trudhesa |
| Mdd US Operations, LLC | $38.11 | 2023-2024 | Gocovri, Apokyn |
| Amneal Pharmaceuticals LLC | $35.57 | 2025 | Brekiya, Crexont |
| Noctrix Health, INC. | $35.05 | 2025 | Nidra |
| Itamar Medical INC | $33.19 | 2025 | Watchpatone |
| Corium, LLC | $30.77 | 2023 | Adlarity |
| Grt US Holding, INC. | $30.08 | 2022 | |
| Alnylam Pharmaceuticals INC. | $26.20 | 2023 | Onpattro |
| Biohaven Pharmaceuticals, INC. | $24.40 | 2021 | |
| Boston Scientific Corporation | $24.03 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $23.58 | 2023 | Relyvrio |
| Janssen Pharmaceuticals, INC | $22.94 | 2022 | |
| Avanir Pharmaceuticals, INC. | $22.62 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $22.62 | 2024 | |
| Impel Pharmaceuticals LLC | $22.36 | 2025 | Trudhesa |
| Merz North America, INC. | $21.92 | 2020 | |
| Cycle Pharmaceuticals INC | $20.97 | 2025 | Tascenso Odt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.65 | 2025 | Rexulti |
| Medtronic, INC. | $20.12 | 2022 | |
| Vanda Pharmaceuticals INC. | $19.13 | 2024 | Ponvory |
| Zoll Respicardia, INC. | $17.27 | 2024 | Remede System |
| Strongbridge US INC. | $14.67 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.75 | 2020 | |
| Life Molecular Imaging LTD | $10.43 | 2023 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gaffney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.